Soluble B7-H1: differences in production between dendritic cells and T cells.

Journal Article (Letter)

Tumor cells aberrantly express several T cell inhibitory molecules including members of the B7-H co-regulatory family. Presumably tumor-expressed B7-H1 and B7-H3 confer resistance to elimination by the immune system. In addition, elevated levels of soluble B7-H1 (sB7-H1) has been identified in the sera of cancer patients, including renal carcinoma patients and is associated with increased cancer related death. Here we report that sB7-H1 is produced and released by activated mature dendritic cells (mDC). Immature DC, macrophages, monocytes, or T cells are refractory to releasing sB7-H1. Exposure of CD4+ and CD8+ T cells to mDC-derived sB7-H1 molecules induced apoptosis. These data suggest that the immunobiology of B7-H1 is perhaps more complex than previously thought. sB7-H1 molecules may represent an unanticipated contributing factor to immune homeostasis. That both immune and tumor cells can be sources of sB7-H1 suggests that optimization of co-regulatory blockade immunotherapy for solid malignancies of necessity will require impact of targeting tumor and immune-derived B7-H1 molecules.

Full Text

Duke Authors

Cited Authors

  • Frigola, X; Inman, BA; Krco, CJ; Liu, X; Harrington, SM; Bulur, PA; Dietz, AB; Dong, H; Kwon, ED

Published Date

  • February 29, 2012

Published In

Volume / Issue

  • 142 / 1-2

Start / End Page

  • 78 - 82

PubMed ID

  • 22138406

Pubmed Central ID

  • PMC3901160

Electronic International Standard Serial Number (EISSN)

  • 1879-0542

Digital Object Identifier (DOI)

  • 10.1016/j.imlet.2011.11.001


  • eng

Conference Location

  • Netherlands